Besponsa(inotuzumab ozogamicin)
Besponsa (inotuzumab ozogamicin) is an antibody drug conjugate pharmaceutical. Inotuzumab ozogamicin was first approved as Besponsa on 2017-06-28. It is used to treat precursor cell lymphoblastic leukemia-lymphoma in the USA. It has been approved in Europe to treat precursor cell lymphoblastic leukemia-lymphoma. The pharmaceutical is active against B-cell receptor CD22.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Mock data
Subscribe for the real data
Subscribe for the real data
Commercial
Therapeutic Areas
Therapeutic Area | MeSH |
|---|---|
| neoplasms | D009369 |
| hemic and lymphatic diseases | D006425 |
| immune system diseases | D007154 |
Trade Name
FDA
EMA
Besponsa
Drug Products
FDA
EMA
Reference product - 351(a)
Reference product - 351(a)
Interchangeable product - 351(k)
Interchangeable product - 351(k)
Biosimilar product - 351(k)
Biosimilar product - 351(k)
Labels
FDA
EMA
Brand Name | Status | Last Update |
|---|---|---|
| besponsa | Biologic Licensing Application | 2024-09-17 |
Indications
FDA
EMA
Indication | Ontology | MeSH | ICD-10 |
|---|---|---|---|
| precursor cell lymphoblastic leukemia-lymphoma | — | D054198 | C91.0 |
Agency Specific
FDA
EMA
Expiration | Code | ||
|---|---|---|---|
inotuzumab ozogamicin, Besponsa, Wyeth Pharmaceuticals LLC | |||
| 2024-08-17 | Orphan excl. | ||
Patent Expiration
No data
HCPCS
Code | Description |
|---|---|
| J9229 | Injection, inotuzumab ozogamicin, 0.1 mg |
Clinical
Clinical Trials
66 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Precursor cell lymphoblastic leukemia-lymphoma | D054198 | — | C91.0 | 3 | 5 | 2 | 2 | 4 | 15 |
| Leukemia | D007938 | — | C95 | 3 | 5 | 2 | 2 | 3 | 14 |
| Lymphoid leukemia | D007945 | — | C91 | 3 | 5 | 2 | 2 | 3 | 14 |
| Precursor b-cell lymphoblastic leukemia-lymphoma | D015452 | — | — | — | — | — | 1 | — | 1 |
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Lymphoma | D008223 | — | C85.9 | 6 | 6 | 2 | — | — | 12 |
| Non-hodgkin lymphoma | D008228 | — | C85.9 | 4 | 2 | 2 | — | — | 7 |
| Follicular lymphoma | D008224 | — | C82 | — | — | 1 | — | — | 1 |
| Aggression | D000374 | EFO_0003015 | — | — | — | 1 | — | — | 1 |
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| B-cell lymphoma | D016393 | — | — | 5 | 4 | — | — | — | 7 |
| Recurrence | D012008 | — | — | 1 | 1 | — | — | — | 2 |
| Large b-cell lymphoma diffuse | D016403 | — | C83.3 | 1 | 2 | — | — | — | 2 |
| Hematopoietic stem cell transplantation | D018380 | — | — | 1 | 1 | — | — | — | 1 |
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Precursor t-cell lymphoblastic leukemia-lymphoma | D054218 | — | — | 1 | — | — | — | — | 1 |
Indications Without Phase
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Hematologic neoplasms | D019337 | — | — | — | — | — | — | 1 | 1 |
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | Inotuzumab ozogamicin |
| INN | inotuzumab ozogamicin |
| Description | Inotuzumab ozogamicin (humanized mab) |
| Classification | Antibody |
| Drug class | monoclonal antibodies; antibiotics (Micromonospora strains) |
| Image (chem structure or protein) |  |
| Structure (InChI/SMILES or Protein Sequence) | — |
Identifiers
| PDB | — |
| CAS-ID | — |
| RxCUI | — |
| ChEMBL ID | CHEMBL2108611 |
| ChEBI ID | — |
| PubChem CID | — |
| DrugBank | DB05889 |
| UNII ID | P93RUU11P7 (ChemIDplus, GSRS) |
Target
Agency Approved
CD22
CD22
Organism
Homo sapiens
Gene name
CD22
Gene synonyms
SIGLEC2
NCBI Gene ID
Protein name
B-cell receptor CD22
Protein synonyms
B-lymphocyte cell adhesion molecule, BL-CAM, CD22, CD22 antigen, Sialic acid-binding Ig-like lectin 2, Siglec-2, T-cell surface antigen Leu-14
Uniprot ID
Mouse ortholog
Cd22 (12483)
B-cell receptor CD22 (Q9WU51)
Alternate
No data
Variants
No data
Financial
Revenue by drug
$
€
£
â‚£
Besponsa – Pfizer
Mock data
Subscribe for the real data
Subscribe for the real data
Mock data
Subscribe for the real data
Subscribe for the real data
Tabular view
Estimated US medical usage
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 1,937 documents
View more details
Safety
Black-box Warning
Black-box warning for: Besponsa
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
2,247 adverse events reported
View more details
© 2020-2025 Collaborative Drug Discovery Inc. (CDD) | Terms of Use